ISSUE BRIEF

Pre-approval Information Exchange (H.R. 9297)

BACKGROUND

The Pre-approval Information Exchange (PIE) Act of 2022 (H.R. 9297) is an important bipartisan policy that will enhance patient access to emerging pharmaceuticals and devices. The PIE Act of 2022, first introduced in March as H.R. 7008, was included as Section 810 of the bipartisan Food & Drug Amendments of 2022 (H.R. 7667) and passed the House of Representatives in June. Like Section 810, H.R. 9297 authorizes pharmaceutical manufacturers to proactively share certain health care economic and scientific information about products with health payers ahead of Food & Drug Administration (FDA) approval.

PIE is a crucial strategy for expediting patient access to new, potentially lifesaving therapies. PIE provides the clarity manufacturers need to feel comfortable proactively disseminating clinical and economic information about pipeline treatments, ensuring health plans and payers have access to critical information and research-based evidence to make timely coverage decisions and facilitate patient access when new therapies come to market. The need for proactive PIE communication is especially important as the health care system evolves from a fee-for-service payment system to a value-based system rewarding quality, improved patient outcomes, and cost-efficiency. PIE will also allow health payers to better anticipate a new indication* and properly plan for its impact on budget and expansion of patient populations eligible to receive a therapy. Further, publicly-funded payers, like Medicare, have limited authority to change their prescription drug formularies during a plan year. In some cases, this can lead to beneficiaries experiencing significant delays accessing new treatments compared to individuals with private insurance.

AMCP'S POSITION

AMCP supports the PIE Act. A legislative safe harbor for PIE will confirm that the proactive dissemination of certain clinical and economic information does not violate the prohibitions against pre-approval promotion and does not run afoul of the labeling, misbranding, and intended use provisions of the Federal Food, Drug, and Cosmetic Act and its implementation regulations. This will expedite coverage decisions for and patient access to emerging therapies, including those granted breakthrough designation.

CALL TO ACTION

AMCP urges Congress to pass PIE before the end of the year and codify safe harbors that allow for proactive PIE between manufacturers and health payers. Sharing truthful and non-misleading clinical and economic information about therapies in the pipeline, as well as new uses of approved products, before FDA approval benefits patients.

* Meaning use of a drug for treatment of a particular disease

CONTACT | JENNIFER L. MATHIEU
Vice President, Policy & Government Relations
314 306 0444 • jmathieu@amcp.org
www.amcp.org • @amcporg